The estimated Net Worth of Alexander A Santini is at least $92.8 Thousand dollars as of 28 February 2020. Alexander Santini owns over 36,263 units of Lexicon Pharmaceuticals Inc stock worth over $92,822 and over the last 8 years Alexander sold LXRX stock worth over $0.
Alexander has made over 3 trades of the Lexicon Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Alexander exercised 36,263 units of LXRX stock worth $61,284 on 28 February 2020.
The largest trade Alexander's ever made was exercising 36,263 units of Lexicon Pharmaceuticals Inc stock on 28 February 2020 worth over $61,284. On average, Alexander trades about 3,773 units every 59 days since 2017. As of 28 February 2020 Alexander still owns at least 54,924 units of Lexicon Pharmaceuticals Inc stock.
You can see the complete history of Alexander Santini stock trades at the bottom of the page.
Alexander's mailing address filed with the SEC is 8800 TECHNOLOGY FOREST PLACE, , THE WOODLANDS, TX, 77381.
Over the last 18 years, insiders at Lexicon Pharmaceuticals Inc have traded over $161,951 worth of Lexicon Pharmaceuticals Inc stock and bought 392,158,422 units worth $731,672,961 . The most active insiders traders include International S.C.A.Minne P..., International S.C.A.Wittouc..., and Llc Invus, L.P.Invus Adviso.... On average, Lexicon Pharmaceuticals Inc executives and independent directors trade stock every 43 days with the average trade being worth of $5,348,701. The most recent stock trade was executed by International S.C.A.Wittouc... on 10 May 2024, trading 57,546,100 units of LXRX stock currently worth $97,252,909.
corporate overview lexicon pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. the genome: our source of discovery we have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. we have integrated a series of recombinant dna and chemistry technologies into a systematic drug discovery and development process. our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. a diverse pipeline of targeted therapies our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indicatio
Lexicon Pharmaceuticals Inc executives and other stock owners filed with the SEC include: